Increased Levels of Eotaxin and MCP-1 in Juvenile Dermatomyositis Median 16.8 Years after Disease Onset; Associations with Disease Activity, Duration and Organ Damage
Objective To compare cytokine profiles in patients with juvenile dermatomyositis (JDM) after medium to long-term follow-up with matched controls, and to examine associations between cytokine levels and disease activity, disease duration and organ damage. Methods Fifty-four JDM patients were examined median 16.8 years (2–38) after disease onset (follow-up) and compared with 54 sex- and age-matched controls. Cytokine concentrations in serum were quantified by Luminex technology. In patients, disease activity score (DAS), myositis damage index (MDI) and other disease parameters were collected by chart review (early parameters) and clinical examination (follow-up). Results Serum levels of eotaxin, monocyte chemoattractant protein-1 (MCP-1) and interferon-inducible protein 10 (IP-10) were elevated in JDM patients compared to controls (31.5%, 37.2% and 43.2% respectively, all p<0.05). Patients with active (n = 28), but not inactive disease (n = 26) had a higher level of MCP-1 than their respective controls. Levels of eotaxin and MCP-1 correlated with disease duration (r = 0.47 and r = 0.64, both p<0.001) and age in patients, but not with age in controls. At follow-up, MDI was associated with MCP-1(standardized β = 0.43, p = 0.002) after adjusting for disease duration and gender. High MDI 1 year post-diagnosis predicted high levels of eotaxin and MCP-1 at follow-up (standardized β = 0.24 and 0.29, both p<0.05) after adjusting for disease duration and gender. Conclusion Patients with JDM had higher eotaxin, MCP-1 and IP-10 than controls. High eotaxin and MCP-1 at follow-up was predicted by early disease parameters, and MCP-1 was associated with organ damage at follow-up, highlighting a role of these chemokines in JDM.
References
[1]
Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, et al. (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 62: 63–72. doi: 10.1002/acr.20015
[2]
Sanner H, Gran JT, Sjaastad I, Flato B (2009) Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology 48: 1541–7. doi: 10.1093/rheumatology/kep302
[3]
Mathiesen PR, Zak M, Herlin T, Nielsen SM (2010) Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol 28: 782–9.
[4]
Oppenheim JJ, Feldman M. (2001) Introduction to the role of cytokines in innate and defense and adaptive immunity. In: Oppenheim JJ FM, ed. Cytokine Reference.New York: Academic Press 3–20.
[5]
De PB, Creus KK, De Bleecker JL (2009) Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 21: 610–6. doi: 10.1097/bor.0b013e3283317b31
[6]
Zong M, Lundberg IE (2011) Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 7: 297–306. doi: 10.1038/nrrheum.2011.39
[7]
Gono T, Kawaguchi Y, Sugiura T, Ichida H, Takagi K, et al. (2010) Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford) 49: 1878–81. doi: 10.1093/rheumatology/keq196
[8]
Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Maslinski W, Olesinska M (2012) Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int 32: 639–43. doi: 10.1007/s00296-010-1692-y
[9]
Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, et al. (2009) Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60: 3436–46. doi: 10.1002/art.24936
[10]
Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, et al. (2013) The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 72: 686–93. doi: 10.1136/annrheumdis-2012-201483
[11]
Schwartz T, Sanner H, Husebye T, Flato B, Sjaastad I (2011) Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 70: 766–71. doi: 10.1136/ard.2010.137968
[12]
Sanner H, Aalokken TM, Gran JT, Sjaastad I, Johansen B, et al. (2011) Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 70: 86–91. doi: 10.1136/ard.2010.131433
[13]
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344–7. doi: 10.1056/nejm197502132920706
[14]
Sanner H, Kirkhus E, Merckoll E, Tollisen A, Roisland M, et al. (2010) Long term muscular outcome, predisposing and prognostic factors in Juvenile Dermatomyositis: - A case control study. Arthritis Care Res 62: 1103–11. doi: 10.1002/acr.20203
[15]
Schwartz T, Sanner H, Gjesdal O, Flato B, Sjaastad I. (2013) In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis; doi:10.1136/annrheumdis-2013-.
[16]
Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM (2003) Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 49: 7–15. doi: 10.1002/art.10924
[17]
Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, et al. (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43: 49–54. doi: 10.1093/rheumatology/keg427
[18]
Sanner H, Sjaastad I, Flato B. (2014) The myositis disease activity assessment tool and the PRINTO criteria for clinically inactive disease applied after long-term follow-up in juvenile onset dermatomyositis. Rheumatology (Oxford): In Press.
[19]
Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41: 22–6. doi: 10.1093/rheumatology/41.1.22
Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, et al. (1995) Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 22: 326–31.
[22]
Vistnes M, Waehre A, Nygard S, Sjaastad I, Andersson KB, et al. (2010) Circulating cytokine levels in mice with heart failure are etiology dependent. J Appl Physiol 108: 1357–64. doi: 10.1152/japplphysiol.01084.2009
[23]
Tucci M, Quatraro C, Dammacco F, Silvestris F (2006) Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 146: 21–31. doi: 10.1111/j.1365-2249.2006.03180.x
[24]
McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, et al. (2006) The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 45: 1255–60. doi: 10.1093/rheumatology/kel099
[25]
Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, et al. (2006) Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 148: 247–53. doi: 10.1016/j.jpeds.2005.10.032
[26]
Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, et al. (2010) Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) 49: 1867–77. doi: 10.1093/rheumatology/keq151
[27]
Baechler EC, Bilgic H, Reed AM (2011) Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 13: 249. doi: 10.1186/ar3531
[28]
Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM (2009) Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 60: 1815–24. doi: 10.1002/art.24555
[29]
Zweifel M, Matozan K, Dahinden C, Schaffner T, Mohacsi P (2010) Eotaxin/CCL11 levels correlate with myocardial fibrosis and mast cell density in native and transplanted rat hearts. Transplant Proc 42: 2763–6. doi: 10.1016/j.transproceed.2010.05.152
[30]
Tacke F, Trautwein C, Yagmur E, Hellerbrand C, Wiest R, et al. (2007) Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol 22: 1256–64. doi: 10.1111/j.1440-1746.2006.04621.x
[31]
Huaux F, Gharaee-Kermani M, Liu T, Morel V, McGarry B, et al. (2005) Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am J Pathol 167: 1485–96. doi: 10.1016/s0002-9440(10)61235-7
[32]
de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, et al. (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66: 589–98. doi: 10.1136/ard.2006.061853
[33]
Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, et al. (2010) Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 62: 383–91. doi: 10.1002/art.27186
[34]
Yadav A, Saini V, Arora S (2010) MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411: 1570–9. doi: 10.1016/j.cca.2010.07.006
[35]
Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, et al. (1996) Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 2: 449–56. doi: 10.1038/nm0496-449
[36]
Martinelli R, Sabroe I, LaRosa G, Williams TJ, Pease JE (2001) The CC chemokine eotaxin (CCL11) is a partial agonist of CC chemokine receptor 2b. J Biol Chem 276: 42957–64. doi: 10.1074/jbc.m103933200
[37]
Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, et al. (2008) Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 58: 1931–9. doi: 10.1002/art.23591
[38]
Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, et al. (2006) A novel, selective, and orally available antagonist for CC chemokine receptor 3. J Pharmacol Exp Ther 317: 244–50.
[39]
Fujii H, Baba T, Ishida Y, Kondo T, Yamagishi M, et al. (2011) Ablation of the Ccr2 gene exacerbates polyarthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 63: 96–106. doi: 10.1002/art.30106
